Editas Medicine Inc (EDIT)

Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten

1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?

The Motley Fool

Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down

Zacks Investment Research

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research

Wall Street Breakfast: The Week Ahead

Seeking Alpha

The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine

Zacks Investment Research

Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More

Zacks Investment Research

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

GlobeNewswire Inc.

Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire Inc.

Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?

Zacks Investment Research

1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.

The Motley Fool

1 Beaten-Down Stock With 55% Upside, According to Wall Street

The Motley Fool

Why Editas Medicine Stock Soared as Much as 42% Higher This Week

The Motley Fool

The Latest Analyst Ratings For Editas Medicine

Benzinga

Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up

Zacks Investment Research

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday

Benzinga

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates

Zacks Investment Research

Bausch (BHC) Q4 Earnings and Revenues Top Estimates

Zacks Investment Research

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

GlobeNewswire Inc.

Bayer (BAYRY) Intends to Slash Dividends Amid Challenges

Zacks Investment Research

Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade

Zacks Investment Research

Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders

Zacks Investment Research

Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology

Zacks Investment Research

5 Biotech Stocks to Consider for Your Portfolio in 2024

Zacks Investment Research

What Makes Editas (EDIT) a New Buy Stock

Zacks Investment Research

2 Under-the-Radar Stocks With Incredible Upside Potential

The Motley Fool

Could Editas Medicine Become the Next CRISPR Therapeutics?

The Motley Fool

Down 88%, Could Editas Medicine Be a Good Investment Now?

The Motley Fool

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

GlobeNewswire Inc.

Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics

The Motley Fool

Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why

Zacks Investment Research

Editas Just Caught a Break Thanks to Vertex Pharmaceuticals

The Motley Fool

Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy

Zacks Investment Research

The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics

Zacks Investment Research

Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News

Zacks Investment Research

Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%

Zacks Investment Research

Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data

Zacks Investment Research

Vertex's stock heads for all-time high as non-opioid painkiller shows promise

MarketWatch

3 Biotechs With Promising Gene Therapies in the Spotlight

Zacks Investment Research

The Latest Analyst Ratings for Editas Medicine

Benzinga

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

GlobeNewswire Inc.

Bull of the Day: CRISPR Therapeutics (CRSP)

Zacks Investment Research

Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment

MarketWatch

Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment

MarketWatch

Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment

MarketWatch

1 Promising Stock Down 66% That Could Skyrocket in 2024

The Motley Fool

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

The Motley Fool

CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here's Why

Zacks Investment Research